Drug Target Collection

HIV-1 protease molecule
HIV-1 protease, molecular model. This enzyme, from HIV (human immunodeficiency virus), cleaves viral polyproteins into functional proteins that are essential for viral assembly and infectivity

Flu virus surface protein and drug F006 / 9745
Flu virus surface protein and drug. Molecular model of the neuraminidase glycoprotein enzyme from on the surface of the influenza A (flu) virus bound to the drug zanamivir

Flu virus surface protein molecule F006 / 9566
Flu virus surface protein molecule. Molecular model of the neuraminidase glycoprotein enzyme found on the surface of the influenza A (flu) virus

RNA stem-loop motif, molecular model F006 / 9544
RNA stem-loop motif. Molecular model of the stem-loop II motif from the SARS (severe acute respiratory syndrome) coronavirus. This RNA (ribonucleic acid) element is a target for antiviral drugs

Aspirin drug target molecule F006 / 9464
Aspirin drug target. Molecular model of the enzyme prostaglandin H2 synthase (PGHS), the target of the anti-inflammatory drug aspirin

Flu virus surface protein molecule F006 / 9433
Flu virus surface protein molecule. Molecular model of the neuraminidase glycoprotein enzyme found on the surface of the influenza A (flu) virus

Flu virus surface protein and antibody F006 / 9428
Flu virus surface protein and antibody. Molecular model of the neuraminidase glycoprotein enzyme found on the surface of the influenza (flu) virus

Tryparedoxin peroxidase molecule C015 / 6441
Tryparedoxin peroxidase. Molecular model of a tryparedoxin peroxidase molecule from the parasitic protozoa Trypanosoma cruzi, the cause of Chagas disease

Tryparedoxin peroxidase molecule C015 / 6440
Tryparedoxin peroxidase. Molecular model of a tryparedoxin peroxidase molecule from the parasitic protozoa Trypanosoma cruzi, the cause of Chagas disease

Flu virus surface protein and antibody. Computer model showing the molecular structure of the neuraminidase glycoprotein enzyme found on the surface of the influenza (flu) virus

Flu virus surface protein molecule. Computer model showing the molecular structure of the neuraminidase glycoprotein enzyme found on the surface of the influenza A (flu) virus

All Professionally Made to Order for Quick Shipping

"Unlocking the Secrets of Drug Targets: From HIV-1 Protease to Flu Virus Surface Protein" In the world of medical research, drug targets play a crucial role in combating various diseases. One such target is the HIV-1 protease molecule, which has been extensively studied to develop effective treatments for HIV/AIDS. Similarly, scientists have focused on understanding the flu virus surface protein and its interaction with antibodies. This knowledge aids in developing vaccines and antiviral drugs that can specifically target this protein, preventing viral entry into our cells. Among these efforts, one notable breakthrough involves the flu virus surface protein and drug F006/9745. Researchers have identified this drug as a potential candidate for inhibiting viral replication by targeting specific regions on the surface protein molecule (F006/9566). Furthermore, investigations into RNA stem-loop motif (molecular model F006/9544) have shed light on its significance as a potential therapeutic target against certain diseases. Scientists are exploring ways to manipulate this structure to develop novel treatment strategies. Interestingly, even common medications like aspirin have their own unique drug targets. The aspirin drug target molecule (F006/9464) has been extensively studied due to its anti-inflammatory properties and cardiovascular benefits. Continuing our exploration of flu-related targets, researchers are closely examining another flu virus surface protein molecule (F006/9433). Understanding its structure and function helps in designing targeted interventions against influenza infections. Moreover, combining antibodies with flu virus surface proteins (F006/9428) shows promise as an approach for neutralizing viral activity effectively. By harnessing these interactions between proteins and antibodies, scientists aim to develop more potent therapies against influenza viruses. Shifting gears back towards HIV/AIDS research highlights the importance of studying both the HIV-1 protease molecule itself and inhibitors that can block its activity. These studies provide valuable insights into designing drugs that can disrupt viral replication processes effectively.